Pfizer said it will waive royalties on sales in all countries covered by the agreement while COVID-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization.
Under the terms of the head license agreement between Pfizer and MPP, qualified generic medicine manufacturers worldwide that are granted sub-licenses will be able to supply Paxlovid (PF-07321332 in combination with ritonavir) to 95 countries, covering up to approximately 53% of the world’s population.
MPP has invited expression of interest (EoI) from potential sublicensees based anywhere in the world for sublicences to manufacture and sell the co-pack of PF-07321332; ritonavir in the licensed territory. The deadline for submitting EoI will be ending on December 6, 2021.
“The agreement will enable MPP to facilitate additional production and distribution of the investigational antiviral, pending regulatory authorization or approval, by granting sub-licenses to qualified generic medicine manufacturers, with the goal of facilitating greater access to the global population,” Pfizer said in a release.
Pfizer earlier this month said the interim data from Phase 2/3 of its experimental antiviral pill Paxlovid which is a combination of PF-07321332 and anti-HIV drug ritonavir, has cut the chance of hospitalisation or death for adults at risk of severe disease by 89%.
MPP last month reached a similar deal with MSD for its Covid antiviral pill, molnupiravir, to be made and sold inexpensively in 105 poorer countries.
Like molnupiravir Indian generic drug makers are once again expected to be in the forefront to seek voluntary licenses to produce Paxlovid as well..
“Pfizer remains committed to bringing forth scientific breakthroughs to help end this pandemic for all people. We believe oral antiviral treatments can play a vital role in reducing the severity of COVID-19 infections, decreasing the strain on our healthcare systems and saving lives,” said Albert Bourla, Chairman and Chief Executive Officer of Pfizer.
“This license is so important because, if authorized or approved, this oral drug is particularly well-suited for low- and middle-income countries and could play a critical role in saving lives, contributing to global efforts to fight the current pandemic,” said Charles Gore, Executive Director of MPP.